Primary objective:
We hypothesize that stratifying patients on clopidogrel into time-based platelet function recovery groups as determined by pre-operative clopidogrel response measured by point of care methods will result in similar rates of bleeding as compared to those of clopidogrel naïve patients undergoing elective CABG.
Study design:
This will be a single center, prospective study analyzing clopidogrel naïve patients and patients on clopidogrel with background aspirin therapy requiring CABG.
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must provide written informed consent.
Patients must currently be on aspirin therapy (81-325 mg).
Male or female patients between the ages of 18-85 requiring CABG.
You may not be if
Patients undergoing emergent surgery following failed percutaneous coronary revascularization.
Patients with a history of previous cardiac surgery and patients needing concomitant valvular surgery.
Pre-operative exposure to either coumadin or platelet GPIIb/IIIa inhibitors.
Patients with a history of bleeding diathesis.
Patients with an activated partial thrombin time \>1.5 normal.
Patients with platelet count \<120,000/mm3.
Patients with hematocrit \<30%.
Patients with creatinine clearance \<30mL/min.
Patients with known active hepatic disease.
Patients with any other condition that, in the opinion of the investigator, may either put the patient at risk or influence the result of the study (e.g. malignancy, limiting life expectancy, noncompliance).
Clareo Health | Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to Coronary Artery Bypass Graft (CABG)
